Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902850 | 0.84 | CYP11B1 (0.34) | CYP11B1CYP11B2MEN1KMT2AAR | |
| SCHEMBL4902602 | 0.84 | KCNH2 (0.32) | — | |
| SCHEMBL4899208 | 0.83 | GABRA5 (0.35) | AR | |
| SCHEMBL4887120 | 0.80 | KCNH2 (0.35) | — | |
| SCHEMBL4896799 | 0.76 | KCNH2 (0.30) | — | |
| SCHEMBL4902060 | 0.75 | HRH1 (0.35) | ARKDM4E | |
| SCHEMBL4903272 | 0.74 | KCNH2 (0.31) | — | |
| SCHEMBL4900200 | 0.73 | KCNH2 (0.34) | — | |
| SCHEMBL4882617 | 0.72 | KCNH2 (0.34) | — | |
| SCHEMBL27590604 | 0.71 | MEN1 (0.37) | CYP11B1CYP11B2MEN1KMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1740550-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | Pfizer Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005100322-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | PFIZER LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | SPR, TPMT, IMPDH1 | CYP11B1 921/4885CYP11B2 1320/4885MEN1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.